Exparel (bupivacaine liposomal) is a brand-name drug prescribed for pain relief after surgery in adults and some children. Exparel comes as an injection that’s given as a single dose by a healthcare ...
PARSIPPANY, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients ...
PARSIPPANY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results from ...
IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management PARSIPPANY, N.J.--(BUSINESS WIRE)-- Pacira ...
Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Pos
Data Presented at Annual Meetings of Leading Regional Anesthesia Societies Demonstrate Analgesia for Up to 72 Hours and High Patient Satisfaction The first study, presented at the 2013 Annual Meeting ...
Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Application ...
BRISBANE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
Exparel (bupivacaine liposome injectable suspension) is prescribed for pain relief after surgery. The drug comes as a suspension. A healthcare professional injects this type of liquid mixture as a one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results